FibroBiologics, Inc. Common Stock
FBLGFibroBiologics, Inc. (FBLG) is a biotechnology company focused on the development and commercialization of regenerative medicine products derived from human fibroblast cells. The company primarily aims to create innovative therapies for wound healing, tissue repair, and other medical applications by leveraging its proprietary cell-based technology platforms.
Company News
FibroBiologics announced completion of cGMP manufacturing for CYWC628 drug product and site onboarding for a phase 1/2 clinical trial in diabetic foot ulcers, with first patient dosing expected in Q2 2026. The company reported positive preclinical results for burn and degenerative disc disease programs, raised $3M in capital, and regained full Na...
Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include...
FibroBiologics priced a public offering of 2.27 million shares and warrants at $1.32 per share, expecting to raise approximately $3 million in gross proceeds before fees. The company also announced successful manufacturing of CYWC628 drug product to support an upcoming diabetic foot ulcer clinical trial. Additionally, the company completed a reve...
The global cell therapy market is projected to surpass $8.2 billion in 2026, with CAR T-cell therapy expanding at 18% annually. Several companies are advancing manufacturing milestones and clinical breakthroughs: Avaà Bio initiated Master Cell Bank production for α-Klotho anti-aging therapy; FibroBiologics secured a patent for fibroblast cell t...
FibroBiologics, a clinical-stage biotechnology company, closed a $4 million registered direct offering by issuing common stock and pre-funded warrants to an existing shareholder, with proceeds intended for general corporate purposes and debt satisfaction.
